You are here

JAMA

JAMA: Leqembi could cost Medicare up to $5B per year

JAMA: Leqembi could cost Medicare up to $5B per year

Medical Marketing and Media

Alzheimer's disease

Flag link:

Study: Half of confirmatory studies for accelerated approvals are late

Study: Half of confirmatory studies for accelerated approvals are late

RAPS.org

accelerated approvals

Flag link:

Study finds manufacturers spend more to advertise less beneficial drugs

Study finds manufacturers spend more to advertise less beneficial drugs

RAPS.org

DTC advertising

pharma advertising

Flag link:

Broken promises? FDA needs more power to remove drugs from marketplace, JAMA analysis finds

Broken promises? FDA needs more power to remove drugs from marketplace, JAMA analysis finds

Endpoints

clinical trials

Flag link:

Study: Public funding was instrumental to early development of COVID therapeutics, vaccines

Study: Public funding was instrumental to early development of COVID therapeutics, vaccines

RAPS.org

Flag link:

JAMA study finds cancer drug data is still largely unavailable to qualified researchers

JAMA study finds cancer drug data is still largely unavailable to qualified researchers

Endpoints

clinical trials

Flag link:

A New JAMA Study Misleads About Drug Prices—And Launches a New Attack on Patients with Ultra-Rare Diseases

A New JAMA Study Misleads About Drug Prices—And Launches a New Attack on Patients with Ultra-Rare Diseases

Drug Channels

Flag link:

Study: FDA approves new oncology drugs quicker than EMA

Study: FDA approves new oncology drugs quicker than EMA

RAPS.org

Flag link:

JAMA Paper Withdrawal Adds One More Layer to Aduhelm Controversy

JAMA Paper Withdrawal Adds One More Layer to Aduhelm Controversy

BioSpace

Alzheimer's disease

Flag link:

FDA staffers defend Aduhelm approval in JAMA editorial

FDA staffers defend Aduhelm approval in JAMA editorial

Pharmaforum

Alzheimer's disease

Flag link:

Americans Are Dying In The Pandemic At Rates Far Higher Than In Other Countries

Americans Are Dying In The Pandemic At Rates Far Higher Than In Other Countries

NPR

Flag link:

Policy makers should ‘set their sights higher’ on U.S. drug pricing regulations, researchers say

Policy makers should ‘set their sights higher’ on U.S. drug pricing regulations, researchers say

MedCity News

Flag link:

Merck CEO Frazier finds fault in new studies suggesting pharma profits are too high

Merck CEO Frazier finds fault in new studies suggesting pharma profits are too high

Fierce Pharma

Flag link:

Researchers Call on FDA to Rethink Guidance Allowing Use of Surrogate Outcomes

Researchers Call on FDA to Rethink Guidance Allowing Use of Surrogate Outcomes

RAPS.org

infectious diseases

drug development

surrogate endpoints

Flag link:

JAMA: Withdraw This Flawed and Inaccurate Article About the 340B Program and Drug Prices

JAMA: Withdraw This Flawed and Inaccurate Article About the 340B Program and Drug Prices

Drug Channels

Flag link:

Financial disclosure lacking in publication of clinical trials, study finds

Financial disclosure lacking in publication of clinical trials, study finds

Science Daily

physician payments

scientific journals

Flag link:

Copay exceeds drug cost in 23% of claims: JAMA research

Copay exceeds drug cost in 23% of claims: JAMA research

Biopharma Dive

Flag link:

Doctors with restricted sales-rep access prescribed fewer promoted meds: JAMA

Doctors with restricted sales-rep access prescribed fewer promoted meds: JAMA

Fierce Pharma

physician access

Flag link:

Amgen refutes 'flawed' cholesterol study

Amgen refutes 'flawed' cholesterol study

BioPharma Dive

PCSK9 inhibitors

Flag link:

Are PCSK9 meds worth the cost? Only if Amgen, Sanofi and Regeneron slash prices by two-thirds: JAMA

Are PCSK9 meds worth the cost? Only if Amgen, Sanofi and Regeneron slash prices by two-thirds: JAMA

Fierce Pharma

PCSK9 inhibitors

Flag link:

Pages